Second-generation antipsychotic use among stimulant-using children, by organization of medicaid mental health

Brendan Saloner1, Meredith Matone, Amanda R Kreider

  • 1Dr. Saloner is with the Department of Health Care Policy, Johns Hopkins University, Baltimore (e-mail: bsaloner@gmail.com ). Ms. Matone, Ms. Kreider, Mr. Budeir, Ms. Miller, and Dr. Rubin are with PolicyLab, Children's Hospital of Philadelphia, Philadelphia. Dr. Rubin is also with the Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Ms. Huang is with Division of General Pediatrics and Healthcare Analytics Unit, Children's Hospital of Philadelphia. Dr. Raghavan is with the George Warren Brown School of Social Work, Washington University in St. Louis, St. Louis, Missouri. Dr. French is with the Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia.

Insights

Managed behavioral health carve-outs were linked to lower second-generation antipsychotic use in children. This contrasts with fee-for-service and integrated care models, highlighting service organization

Area of Science:

  • Health Services Research
  • Pediatric Psychiatry
  • Health Policy

Background:

  • Overuse of second-generation antipsychotics (SGAs) in children enrolled in Medicaid is a significant concern.
  • Understanding how different Medicaid service organization structures impact SGA utilization is crucial for policy development.
  • Limited research exists on the comparative effectiveness of fee-for-service, integrated managed care, and managed behavioral health carve-out models in pediatric SGA use.

Purpose of the Study:

  • To compare second-generation antipsychotic utilization rates among Medicaid-enrolled children across three distinct service organization structures: fee-for-service, integrated managed care, and managed behavioral health carve-outs.
  • To identify which organizational structures are associated with higher or lower rates of antipsychotic prescribing in pediatric populations.

Main Methods:

  • Cross-sectional analysis of child-level claims data from the Medicaid Analytic Extract (2004, 2006, 2008) across 82 counties in 34 states.
  • Sample restricted to stimulant-using children aged 3-18 (N=419,226) to approximate the population at risk for antipsychotic treatment.
  • Logistic regression models estimated SGA use probability, with county-level organizational structure as a primary predictor, adjusting for individual and county covariates.

Main Results:

  • Youth in foster care using SGAs were 31% more likely in fee-for-service counties compared to carve-out counties (OR=1.69).
  • Foster care youth in integrated managed care counties showed the second-highest adjusted odds of SGA use (OR=1.31).
  • Similar patterns were observed for Supplemental Security Income-eligible youth, but not for Temporary Assistance for Needy Families recipients; differences persisted after covariate adjustment.

Conclusions:

  • Managed behavioral health carve-outs were associated with significantly lower second-generation antipsychotic use among Medicaid-enrolled children compared to fee-for-service and integrated managed care models.
  • Further investigation into specific features of carve-out models, such as enhanced inpatient management or restricted access protocols, is warranted.
  • Care coordination mechanisms within carve-out structures may contribute to reduced antipsychotic prescribing, offering potential strategies for optimizing pediatric mental healthcare delivery.
Abstract

Related Concept Videos

Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...